Tobira Therapeutics (TBRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2015 | 12-2014 | 09-2014 | 06-2014 | 03-2014 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -7,032 | -24,100 | -13,686 | -10,746 | -15,848 |
| Depreciation Amortization | 291 | 2,075 | 1,764 | 1,129 | 91 |
| Accounts payable and accrued liabilities | 1,093 | 2,852 | N/A | 1,861 | -267 |
| Other Working Capital | 1,852 | 1,432 | 359 | 1,778 | 1,782 |
| Other Operating Activity | -2,178 | -924 | 863 | 1,142 | 825 |
| Operating Cash Flow | $-5,974 | $-18,665 | $-10,700 | $-4,836 | $-13,417 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -22 | -180 | -130 | -63 | -47 |
| Purchase Sale Intangibles | N/A | N/A | N/A | N/A | -140 |
| Other Investing Activity | 0 | 0 | 0 | 0 | -1,140 |
| Investing Cash Flow | $-22 | $-180 | $-130 | $-63 | $-1,187 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 13,000 | 22,776 | 22,806 | 22,888 | N/A |
| Debt Repayment | -5 | -1,841 | -1,833 | -1,833 | 0 |
| Common Stock Issued | N/A | N/A | N/A | N/A | 18,853 |
| Other Financing Activity | 0 | 0 | -2,423 | -1,481 | -99 |
| Financing Cash Flow | $12,995 | $20,935 | $18,550 | $19,574 | $18,754 |
| Beginning Cash Position | 6,178 | 4,088 | 4,088 | 4,088 | 30,688 |
| End Cash Position | 13,177 | 6,178 | 11,808 | 18,763 | 34,838 |
| Net Cash Flow | $6,999 | $2,090 | $7,720 | $14,675 | $4,150 |
| Free Cash Flow | |||||
| Operating Cash Flow | -5,974 | -18,665 | -10,700 | -4,836 | -13,417 |
| Capital Expenditure | -22 | -180 | -130 | -63 | -47 |
| Free Cash Flow | -5,996 | -18,845 | -10,830 | -4,899 | -13,464 |